Harrow, Inc. announced the relaunch of TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL, an FDA-approved, preservative-free synthetic corticosteroid. This product is indicated for visualization during vitrectomy and for treating ocular inflammatory conditions unresponsive to topical corticosteroids. The relaunch follows TRIESENCE's absence from the U.S. market for over five years, during which it was listed on the FDA Drug Shortage List.
The return of TRIESENCE provides ophthalmologists with access to a trusted treatment option, replacing less ideal, off-label solutions previously used. Harrow rebuilt the entire TRIESENCE supply chain through a global collaboration to achieve this relaunch. This initiative is expected to improve surgical outcomes and patient care by offering a safer and more effective treatment.
TRIESENCE is available in a single-use vial of 40 milligrams per milliliter. Healthcare providers can order the product directly through major pharmaceutical specialty distributors, including Besse Medical/Cencora, McKesson Medical-Surgical, and Cardinal Health. Initial supplies are listed under NDCs 00078-0897-78 and 82667-800-01.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.